Claims
- 1. An immunogenic composition comprising an immunogenic peptide fragment of vascular endothelial growth factor, wherein the immunogenic peptide fragment consists of SEQ ID No: 3, SEQ ID No: 4, SEQ ID No: 5, SEQ ID No: 6, SEQ ID No: 7, SEQ ID No: 8, or SEQ ID No: 9; and a pharmaceutically acceptable carrier.
- 2. The composition of claim 1, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.
- 3. The composition of claim 2, wherein the carrier protein comprises maltose binding protein, bovine serum albunim, keyhole lympet hemocyanin, ovalbumin, flagellin, thyroglobulin, serum albumin, gamma globulin, syngeneic cells, and polymers of D- and/or L-amino acids.
- 4. The composition of claim 2, further comprising adjuvants, preservatives, diluents, emulsifiers, and stabilizers.
- 5. The composition of claim 4, wherein the adjuvant is selected from the group consisting of lipophilic muramyl dipeptide derivatives, nonionic block polymers, aluminum hydroxide, aluminum phosphate, lipid A, Freund's incomplete adjuvant, Freund's complete adjuvant, polydispersed β-(1,4) linked acetylated mannan, polyoxyethylene-polyoxypropylene copolymer adjuvants, saponin derivative adjuvants, killed Bordetella pertussis, lipopolysaccharide of gram-negative bacteria, polymeric anions, dextran sulfate, inorganic gels, alum, aluminum hydroxide, and aluminum phosphate.
- 6. The composition of claim 1, further comprising a hydrophobic moiety attached to the immunogenic peptide.
- 7. The composition of claim 6, wherein the hydrophobic moiety comprises at least one long chain fatty acid having at least 10 carbon atoms in the lipid backbone.
- 8. The composition of claim 6, wherein the hydrophobic moiety is selected from the group consisting of palmitic acid, stearic acid, myristic acid, lauric acid, oleic acid, linoleic acid, and linolenic acid.
- 9. An immunogenic composition comprising an immunogenic peptide fragment of vascular endothelial growth factor, wherein the immunogenic peptide fragment consists of SEQ ID No: 6, and a pharmaceutically acceptable carrier.
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application is a continuation-in-part application of U.S. patent application Ser. No. 09/265,213 filed Mar. 10, 1999 (now abandoned) which is a non-provisional application of U.S. Provisional Patent Application Ser. No. 6/077,460 filed Mar. 10, 1998. The present application is also a continuation-in-part application of 08/467,101, filed Jun. 6, 1995, now U.S. Pat. No 5,919,459 issued on Jul. 6, 1999, which is a continuation application of U.S. patent application Ser. No. 08/271,557 filed Jul. 7, 1994 (now abandoned), which is a continuation of U.S. patent application Ser. No. 08/068,717 filed May 27, 1993 (now abandoned).
US Referenced Citations (7)
Number |
Name |
Date |
Kind |
5252718 |
Baird et al. |
Oct 1993 |
A |
5288704 |
Ungheri et al. |
Feb 1994 |
A |
5629327 |
D'Amato |
May 1997 |
A |
5733876 |
O'Reilly et al. |
Mar 1998 |
A |
5792845 |
O'Reilly et al. |
Aug 1998 |
A |
5854205 |
O'Reilly et al. |
Dec 1998 |
A |
5919459 |
Nacy et al. |
Jul 1999 |
A |
Foreign Referenced Citations (1)
Number |
Date |
Country |
0 281 822 |
Sep 1988 |
EP |
Non-Patent Literature Citations (4)
Entry |
Kardami, E. et al. Characterization of two preparation of antibodies to basic fibroblast growth factor which exhibit distinct patterns of immunolocalization. Growth Factors, 4: 69-80, 1990.* |
Baird, et al., “Receptor-and Heparin Binding Domains of Basic Fibroblast Growth Factor”, Proc. Natl. Acad. Sci. USA , vol. 85, Apr., pp. 2324-2328 (1988). |
Seaver, “Monoclonal Anigbodies in Industry: More Difficult than Originally Thought”, Genetic Engineering News, vol. 14, Aug., pp. 10 and 21 (1994). |
Soker, et al., “Neuropilin-1 is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor”, Cell, vol. 92, Mar., pp. 735-745 (1998). |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/077460 |
Mar 1998 |
US |
Continuations (2)
|
Number |
Date |
Country |
Parent |
08/271557 |
Jul 1994 |
US |
Child |
08/467101 |
|
US |
Parent |
08/068717 |
May 1993 |
US |
Child |
08/271557 |
|
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
09/265213 |
Mar 1999 |
US |
Child |
09/266543 |
|
US |
Parent |
08/467101 |
Jun 1995 |
US |
Child |
09/265213 |
|
US |